SCHEMBL660463

SCHEMBL660463

O=C(O)CNCCc1c[nH]c2ccccc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC5R P33032 1/20 0.66
MC3R P41968 1/20 0.66
MC1R Q01726 1/20 0.66
KMT2A Q03164 6/20 0.64
MEN1 O00255 5/20 0.64
NPC1 O15118 1/20 0.64
RAB9A P51151 1/20 0.64
HTR2A P28223 2/20 0.64
LMNA P02545 1/20 0.63
CYP1A2 P05177 1/20 0.63
PKM P14618 1/20 0.63
TSHR P16473 1/20 0.63
CYP2C19 P33261 1/20 0.63
BLM P54132 1/20 0.63
G6PD P11413 1/20 0.61
MMP9 P14780 1/20 0.60
AANAT Q16613 1/20 0.60
FAAH O00519 1/20 0.60
MAPT P10636 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29489675 1.00 MC5R (0.66) MC5RMC3RMC1RKMT2AMEN1
SCHEMBL5939865 0.90 MC5R (0.64) MC5RMC3RMC1RKMT2AMEN1
SCHEMBL3427633 0.87 MC5R (0.64) MC5RMC3RMC1RKMT2AMEN1
SCHEMBL29874992 0.85 MC1R (0.60) MC5RMC3RMC1RKMT2AMEN1
SCHEMBL250139 0.85 MC1R (0.60) MC5RMC3RMC1RKMT2AMEN1
SCHEMBL9542634 0.85 HTR2A (0.63) MC5RMC3RMC1RKMT2AMEN1
SCHEMBL7037221 0.84 MC5R (0.73) MC5RMC3RMC1RKMT2AMEN1
SCHEMBL17232881 0.84 MC5R (0.83) MC5RMC3RMC1RKMT2AMEN1
Indolylpropionic Acid SCHEMBL29521227 0.83 MAPT (0.68) KMT2AMEN1NPC1RAB9AHTR2A
Indolylpropionic Acid SCHEMBL195405 0.83 MAPT (0.68) KMT2AMEN1NPC1RAB9AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12589171-B2 177-Lu labeled peptide for site-specific uPAR-targeting TRT INNOVATIONS APS (DK) 2026-03-31 US claimed
EP-4448020-B1 UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS CURASIGHT AS (DK) 2026-02-04 EP claimed
EP-4678194-A1 THERAPEUTIC APPLICATION OF 64CU-LABELLED CONJUGATES FOR SITE-SPECIFIC UPAR-TARGETING Curasight A/S (DK) 2026-01-14 EP claimed
EP-4651912-A1 RADIONUCLIDE LABELLED PEPTIDE CONJUGATE FOR SITE-SPECIFIC UPAR-TARGETING Curasight A/S (DK) 2025-11-26 EP claimed
US-20250319215-A1 UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS) CURASIGHT AS (DK) 2025-10-16 US claimed
US-12409240-B2 Positron emitting radionuclide labeled peptides for human uPAR PET imaging CURASIGHT A/S (DK) 2025-09-09 US claimed
US-20250049971-A1 UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS CURASIGHT A/S (DK) 2025-02-13 US claimed
WO-2024153756-A1 RADIONUCLIDE LABELLED PEPTIDE CONJUGATE FOR SITE-SPECIFIC UPAR-TARGETING CURASIGHT A/S (DK) 2024-07-25 WO claimed
EP-3590542-B1 POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING CURASIGHT AS (DK) 2024-01-03 EP claimed
EP-4197561-A1 UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS Curasight A/S (DK) 2023-06-21 EP claimed
US-20220202966-A1 POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING CURASIGHT A/S (DK) 2022-06-30 US claimed
US-11311637-B2 Positron emitting radionuclide labeled peptides for human uPAR PET imaging CURASIGHT A/S (DK) 2022-04-26 US claimed
EP-1621546-B1 Peptide ligands specific to immonoglobulins TECNOGEN SPA (IT) 2008-10-29 EP claimed
US-7026282-B1 Peptide antagonists of the human urokinase receptor and method for selecting them Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) (DK) 2006-04-11 US claimed
EP-1621546-A1 Peptide ligands specific to immonoglobulins TECNOGEN S.C.P.A. (IT) 2006-02-01 EP claimed
WO-2000001802-A2 PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR AND METHOD FOR SELECTING THEM CANCERFORSKNINGSFONDEN AF 1989 (FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING) (DK) 2000-01-13 WO claimed
US-20260140060-A1 COLORIMETRIC DETECTION OF A VIRAL INFECTION RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2026-05-21 US disclosed
US-20260124281-A1 FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE ENTERA BIO LTD. (IL) 2026-05-07 US disclosed
WO-1994003483-A1 ENDOTHELIN RECEPTOR-BINDING COMPOUNDS CHIRON CORPORATION (US) 1994-02-17 WO disclosed
US-4904655-A Novel indolo [3,2,1-de] [1,4] oxazino [2,3,4-ij] [1,5] ROUSSEL UCLAF (FR) 1990-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12589171-B2 177-Lu labeled peptide for site-specific uPAR-targeting LNPEP, XPNPEP2, PLAUR MC5R 1499/4885MC3R 600/4885MC1R 654/4885
US-20220202966-A1 POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING PLAUR, PLAU, SERPINE1 MC5R 1481/4885MC3R 899/4885MC1R 229/4885
US-20260124281-A1 FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE PTH1R, FGF23, PTMS MC5R 326/4885MC3R 167/4885MC1R 1028/4885
US-12409240-B2 Positron emitting radionuclide labeled peptides for human uPAR PET imaging PLAUR, PLAU, SERPINE1 MC5R 1481/4885MC3R 899/4885MC1R 229/4885
US-11311637-B2 Positron emitting radionuclide labeled peptides for human uPAR PET imaging PLAUR, PLAU, SERPINE1 MC5R 1481/4885MC3R 899/4885MC1R 229/4885
US-20250049971-A1 UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS PLAUR, PLAU, PROKR1 MC5R 95/4885MC3R 160/4885MC1R 64/4885
US-20250319215-A1 UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS) PLAUR, PLAU, SERPINE1 MC5R 792/4885MC3R 712/4885MC1R 240/4885
US-20260140060-A1 COLORIMETRIC DETECTION OF A VIRAL INFECTION CTSL, CPA4, ACE2 MC5R 2348/4885MC3R 1653/4885MC1R 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.